1. Viatris Launches Its Interchangeable Insulin Biosimilar
Biocon and Viatris have launched their interchangeable insulin biosimilar, Semglee, which references Sanofi's Lantus. The companies are offering two versions of the medication, branded and unbranded, at different price points. The decision encourages payers to choose between a higher-priced product with a larger rebate or a lower-priced option with a smaller discount, according to Bernstein analyst Ronny Gal.
2. AstraZeneca's China Business Slows Amid Tagrisso Price Cut
AstraZeneca's China business posted only a 2% year-over-year sales growth in the third quarter, a stark contrast to the double-digit growth it has enjoyed in recent years. Lung cancer drug Tagrisso struggled as the volume expansion hasn't yet compensated for the lower prices the company agreed to in order to secure frontline approval in national reimbursement. However, AZ expects its first China approval for its Alexion rare disease portfolio in 2022.
3. Chinese Drug Manufacturer Overcomes FDA Warning After Global Valsartan Recall
After initiating a global recall of valsartan three years ago, a Chinese drug manufacturer has successfully resolved the FDA warning letter issued during that time.
No comments:
Post a Comment